Search

Your search keyword '"Massironi, S."' showing total 339 results

Search Constraints

Start Over You searched for: Author "Massironi, S." Remove constraint Author: "Massironi, S." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
339 results on '"Massironi, S."'

Search Results

2. Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms

3. Distinguishing features of autoimmune gastritis depending on previous H. pylori infection or positivity to anti-parietal cell antibodies: Results from the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)

4. Eosinophilic esophagitis: does age matter?

5. OC.15.3: INCIDENCE AND CHARACTERISTICS OF ENDOSCOPIC GASTRIC POLYPS IN PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS: A MULTICENTRIC RETROSPECTIVE STUDY

7. Assessing the Frequency of Type I Gastric Neuroendocrine Neoplasms in Autoimmune Atrophic Gastritis: A Multi-Center Study in Italy

8. Incidence and Characteristics of Endoscopic Gastric Polyps in Patients with Autoimmune Atrophic Gastritis: A Multicentric Retrospective Study

10. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

11. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

15. Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies?

16. Paradoxical association between dyspepsia and autoimmune chronic atrophic gastritis: Insights into mechanisms, pathophysiology, and treatment options

17. Sporadic and MEN1-related gastrinoma and Zollinger–Ellison syndrome: differences in clinical characteristics and survival outcomes

18. Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: A systematic review and meta-analysis

19. Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review

20. Use of IBD Drugs in Patients with Hepatobiliary Comorbidities: Tips and Tricks

21. Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis

22. Exploring the spectrum of incidental gastric polyps in autoimmune gastritis

23. Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance

24. Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?

25. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: Interim analysis of prospective ASPEN trial

26. Clinical challenge for gastroenterologists–Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review

27. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

28. Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study

33. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

37. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

38. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

39. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

40. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies

41. Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy

42. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

43. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

44. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis

45. Understanding short bowel syndrome: Current status and future perspectives

46. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study

47. COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy

48. Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19”

49. Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management

50. Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy

Catalog

Books, media, physical & digital resources